Recoverable Foundation

Recovery Library

Doc #42 — Contraception and Family Planning

Managing Reproductive Choice Under Supply Constraints

Phase: 1–3 (Months 0 through Years 3–7) | Feasibility: [B] Achievable

Unreliable — not for operational use. Produced by AI under human direction and editorial review. This document contains errors of fact, judgment, and emphasis and has not been peer-reviewed. See About the Recovery Library for methodology and limitations. © 2026 Recoverable Foundation. Licensed under CC BY-ND 4.0. This disclaimer must be included in any reproduction or redistribution.

EXECUTIVE SUMMARY

An uncontrolled increase in birth rate under nuclear winter food rationing adds thousands of additional dependents per year, increasing demand on every recovery system — food, medical care, housing, education — at precisely the time those systems have the least capacity. NZ’s contraceptive supplies are entirely imported: oral contraceptive pills, condoms, injectable contraceptives, subdermal implants, and intrauterine devices all come from overseas manufacturers.1 When global supply chains are permanently severed, the contraceptive methods currently in the country — in wholesale warehouses, pharmacy shelves, clinic stores, and patients’ homes — are the total supply until domestic alternatives are developed or trade resumes.

The demographic consequences of this supply gap are significant and compounding. NZ currently has approximately 60,000 births per year.2 If contraceptive availability declines substantially, unintended pregnancy rates will increase, and the birth rate could rise to 70,000–80,000 or more per year within 5–10 years.3 Each additional birth places demand on food supply (Doc #3), medical care (Doc #123), housing (Doc #162), and education (Doc #157) — all of which are already under strain. A sustained 25–30% increase in birth rate over a decade adds roughly 50,000–80,000 additional people to the population beyond what baseline planning assumes. Under nuclear winter food constraints, this is not trivial.

This document addresses managed reproductive choice — not population control. The distinction matters practically as well as ethically. Coercive population measures destroy public trust, provoke non-compliance, and produce social damage that undermines recovery. Voluntary access to effective contraception, by contrast, is one of the highest-value, lowest-cost health interventions available: it reduces maternal mortality (fewer high-risk pregnancies), reduces infant mortality (better-spaced births), improves maternal and child nutrition (smaller family sizes under rationing), and frees workforce capacity (fewer people in the dependency ratio). The goal is to ensure that individuals and families can make informed reproductive decisions despite constrained supply — and that the recovery programme accounts for the demographic consequences of whatever decisions they make.

The good news: copper IUDs — the single most effective long-acting reversible contraceptive — are potentially fabricable from NZ materials. A copper IUD is a small T-shaped frame with copper wire wound around it. The copper itself is available in NZ (electrical wire stock is abundant), and the fabrication, while requiring precision and sterility, does not require complex chemistry or imported reagents. If NZ can train sufficient insertion practitioners and establish sterile fabrication, locally made copper IUDs could provide effective long-acting contraception indefinitely. This is the centrepiece of the long-term strategy.

Contents

Phase 1 — First two weeks [IMMEDIATE to URGENT]

  1. Inventory all contraceptive stocks nationally. Integrate with the Doc #4/Doc #116 national pharmaceutical inventory. Include oral contraceptive pills (all formulations), injectable medroxyprogesterone acetate (Depo-Provera), levonorgestrel subdermal implants (Jadelle), copper IUDs (Multiload, TCu380A, or equivalent), hormonal IUDs (Mirena, Kyleena), and condom stocks held by wholesale distributors, pharmacies, Family Planning clinics, and hospital stores.4 [Phase: 1 — IMMEDIATE]

  2. Issue rationing guidance for contraceptive prescribing. Prioritise long-acting reversible contraceptives (LARCs) — IUDs and implants — over short-acting methods (pills, injectables) in all new contraceptive starts. Every IUD or implant inserted now is 5–10 years of contraception that does not draw on ongoing pill or injectable stocks. [Phase: 1 — URGENT]

  3. Preserve condom stocks for STI prevention. Condom supplies should be rationed with dual-use in mind — contraception plus sexually transmitted infection prevention. Where a person is using a LARC for pregnancy prevention, condoms should be available specifically for STI prevention rather than as a primary contraceptive. [Phase: 1 — URGENT]

Phase 1 — First three months [HIGH PRIORITY]

  1. Maximise LARC insertions. Family Planning NZ, community midwives, and GPs with LARC insertion training should be directed to offer copper IUD and implant insertion to all women who want long-acting contraception. This is a time-limited opportunity — once stocks are depleted, only locally fabricated devices will remain. [Phase: 1]

  2. Begin fertility awareness method (FAM) education programme. Train community health workers, midwives, and GPs to teach fertility awareness methods (sympto-thermal method, cervical mucus monitoring, calendar-based methods). These are the only contraceptive methods that require no manufactured supplies. Education should begin while pharmaceutical contraception is still available, so skills are established before they are relied upon. [Phase: 1]

  3. Identify and register all LARC insertion practitioners. NZ has an estimated 1,500–2,000 practitioners trained in IUD and/or implant insertion (GPs, midwives, Family Planning clinicians, gynaecologists).5 Not all are currently practising these skills. Establish a national register and begin planning for training expansion. [Phase: 1]

Phase 1–2 — Months 3–18 [PRIORITY]

  1. Develop copper IUD local fabrication programme. Establish a prototype fabrication process using NZ copper wire, with sterilisation using autoclave or ethylene oxide. Testing and quality assurance protocol developed in partnership with obstetric/gynaecological specialists. See Section 4. [Phase: 1–2]

  2. Expand LARC insertion training. Train additional practitioners — particularly midwives and nurses in rural areas — in IUD and implant insertion. Target: double the number of active insertion practitioners within 12 months. [Phase: 1–2]

  3. Develop cervical cap/diaphragm fabrication. Assess feasibility of producing barrier devices from available rubber or silicone stocks. Lower priority than copper IUD programme but provides an additional non-hormonal option. [Phase: 1–2]

  4. Condom alternative: lambskin membrane. Assess feasibility of producing condoms from lamb caecum (the historical method). NZ’s sheep flock provides the raw material. Lambskin condoms do not prevent STI transmission but provide contraceptive protection. See Section 5. [Phase: 2]

Phase 2–3 — Years 1–7 [STRATEGIC]

  1. Scale copper IUD production to meet national demand. Target: 15,000–25,000 devices per year (see Section 4 for demand estimate). [Phase: 2–3]

  2. Integrate family planning into demographic planning. Collaborate with Doc #3 (food rationing), Doc #145 (workforce reallocation), Doc #157 (education), and Doc #163 (housing) to model population growth scenarios under different contraceptive availability assumptions. Adjust planning parameters annually based on actual birth rate data. [Phase: 2–3]

  3. Monitor and publish demographic data. Birth rate, fertility rate, contraceptive prevalence — tracked and published quarterly. Decision-makers need this data; the public deserves transparency. [Phase: 2–3]

ECONOMIC JUSTIFICATION

The cost of unplanned population growth

Under food rationing (Doc #3), each additional person requires approximately 2,000–2,500 kilocalories per day. An additional 10,000 births per year — a plausible increase if contraceptive access declines — adds roughly 7–9 billion kilocalories per year of food demand by Year 5, growing each subsequent year as the cohort ages. Under nuclear winter food constraints, this is not a marginal burden. It is the difference between adequate and inadequate caloric supply for some communities.

Each additional birth also requires maternity care (Doc #123) at a time when maternity consumables are depleting, and each surviving child requires years of dependency before contributing to the workforce.

The cost of the contraceptive programme

Copper IUD fabrication: Once established, requires minimal ongoing inputs — copper wire, a small sterile fabrication workshop, and trained insertion practitioners. Estimated establishment cost: 5–10 person-years of specialist labour (materials science, medical device fabrication, quality assurance — this estimate assumes access to existing autoclave infrastructure and does not include training insertion practitioners, which is counted separately). Ongoing production cost: perhaps 2–5 full-time-equivalent workers for national-scale output.

Fertility awareness education: Requires trained educators, printed materials, and thermometers (basal body temperature method). No ongoing consumable cost. Estimated programme establishment: 5–10 person-years to train an initial cadre of community educators.

Total programme cost: Roughly 10–20 person-years of establishment labour, plus 5–10 FTE ongoing. This is negligible relative to the downstream costs of 10,000–20,000 additional unplanned births per year over a decade — each requiring food, housing, medical care, and education infrastructure.

Breakeven: Immediate. Every prevented unplanned pregnancy under rationing conditions avoids 18+ years of dependency costs that exceed the marginal cost of contraceptive provision by orders of magnitude.

1. CURRENT CONTRACEPTIVE USE IN NZ

1.1 Methods and prevalence

Approximately 250,000–300,000 NZ women of reproductive age use some form of modern contraception at any given time.6 The method mix, based on NZ prescribing data and Family Planning NZ reports, is approximately:78

Method Estimated NZ users Annual supply requirement Stock type
Combined oral contraceptive pill ~120,000–150,000 ~120,000–150,000 packs/year (13 cycles each) Imported. Tablet blister packs.
Progestogen-only pill ~30,000–50,000 ~30,000–50,000 packs/year Imported. Tablet blister packs.
Levonorgestrel implant (Jadelle) ~25,000–35,000 in situ New insertions: ~5,000–8,000/year; replacement every 5 years Imported. Subdermal implant rods.
Copper IUD (various) ~15,000–25,000 in situ New insertions: ~5,000–8,000/year; replacement every 5–10 years Imported. Copper-wound plastic frame.
Hormonal IUD (Mirena/Kyleena) ~30,000–45,000 in situ New insertions: ~10,000–15,000/year; replacement every 5–8 years Imported. Hormone-releasing device.
Injectable (Depo-Provera) ~15,000–25,000 ~60,000–100,000 injections/year (quarterly) Imported. Injectable solution.
Condoms (male) Widespread but intermittent use Millions per year Imported. Latex.

Note: These figures are estimates based on PHARMAC dispensing data, Family Planning NZ reports, and NZ Health Survey data. Precise aggregate figures are not publicly available for all methods.910

1.2 Supply chain and current stocks

All contraceptive methods are imported through the same pharmaceutical supply chain described in Doc #4. PHARMAC funds most hormonal contraceptives, IUDs, and implants. Condoms are primarily purchased commercially rather than through PHARMAC. Family Planning NZ (approximately 30 clinics nationwide) is the largest single provider of LARC services.11

Estimated in-country stock at any time: 3–6 months of oral contraceptive pills; perhaps 6–12 months of IUDs and implants (lower turnover items with deeper buffer stocks); 3–6 months of condoms.12 These estimates are based on standard pharmaceutical pipeline norms for NZ’s wholesaler-to-pharmacy supply chain and would need verification through the Doc #4 national inventory process.

2. DEPLETION TIMELINES

2.1 Method-by-method depletion

Oral contraceptive pills: Shelf life 3–5 years from manufacture. Under SLEP-based extension (Doc #116), oral contraceptive pills are solid dose formulations that likely retain potency for 5–8 years or more beyond manufacture. However, hormonal potency degradation may affect contraceptive reliability differently from therapeutic drugs — a 10% decline in analgesic potency is clinically acceptable, but a 10% decline in contraceptive hormone dose may reduce efficacy. Conservative SLEP extension for oral contraceptives: perhaps 2–3 years beyond labeled expiry, giving a total usable life of approximately 5–8 years from manufacture.13

Estimated total usable supply: 3–6 years at current consumption rates, assuming SLEP extension and strict rationing (prioritising women not suitable for LARCs). If LARC uptake increases substantially — reducing pill demand — pill stocks could last 5–8 years.

Injectable contraceptives (Depo-Provera): Medroxyprogesterone acetate suspension in vials. Shelf life approximately 3–5 years. SLEP extension potential is moderate for injectable suspensions — less than for solid dose forms. Estimated usable supply: 3–5 years.

Subdermal implants (Jadelle): Each implant lasts 5 years in situ. Women with implants currently in place have contraception for the remaining life of the device. New insertions draw down stock. Once stock is exhausted, no new insertions are possible — the silicone rod and levonorgestrel formulation cannot be replicated locally. Estimated total stock life: existing in-situ devices provide contraception through their duration (up to 5 years); new insertions from warehouse stock continue for perhaps 1–3 years depending on stock levels and insertion rate.

Copper IUDs: Each device lasts 5–10 years in situ (TCu380A is approved for 10 years).14 Women with copper IUDs currently in place have the longest-duration contraception of any existing method. New insertions from imported stock continue for perhaps 1–3 years. After that, locally fabricated devices become the primary source.

Hormonal IUDs (Mirena/Kyleena): Each device lasts up to 8 years (Mirena, per updated approval data) or 5 years (Kyleena).15 Similar stock trajectory to copper IUDs, but without the local fabrication option — the levonorgestrel reservoir system requires pharmaceutical-grade hormone formulation and controlled-release polymer technology that cannot be replicated locally.

Condoms: Latex condoms have a shelf life of approximately 3–5 years (longer for non-lubricated). Latex degrades through oxidation and UV exposure; proper storage in cool, dark conditions extends life. NZ does not produce natural rubber latex — there are no rubber tree (Hevea brasiliensis) plantations in NZ’s climate. Imported condom stocks are finite. Estimated total usable supply: 3–5 years at rationed distribution rates.16

2.2 The transition gap

The critical period is Years 3–7 — after imported hormonal methods and condoms are largely depleted but before locally fabricated copper IUDs and fertility awareness education have scaled to meet demand. During this gap, unintended pregnancy rates will rise unless the transition is actively managed. The recommended actions timeline is designed to minimise this gap by front-loading LARC insertions (using imported stock while it lasts) and fertility awareness education (building skills before they are needed).

3. FERTILITY AWARENESS METHODS

Feasibility: [A] — requires only education and thermometers, both available in NZ. Effectiveness is the constraint, not feasibility.

3.1 What they are

Fertility awareness-based methods (FABMs) identify the fertile window in a woman’s menstrual cycle through one or more biomarkers — basal body temperature, cervical mucus changes, calendar calculations, or combinations thereof. Intercourse is avoided (or barrier methods used) during the identified fertile period.17

Methods available without manufactured supplies:

  • Sympto-thermal method: Combines basal body temperature measurement with cervical mucus observation. Requires a thermometer (mercury or digital — existing stocks are substantial) and daily charting. Perfect-use failure rate: approximately 0.4–2% per year. Typical-use failure rate: approximately 12–22% per year.1819
  • Cervical mucus method (Billings method): Relies on cervical mucus observation alone. No equipment needed beyond education. Perfect-use failure rate: approximately 3% per year. Typical-use failure rate: approximately 14–24% per year.20
  • Standard Days Method (calendar-based): Identifies cycle days 8–19 as the fertile window for women with regular 26–32 day cycles. Requires only a means of tracking days. Perfect-use failure rate: approximately 5% per year. Typical-use failure rate: approximately 12–24% per year.21

3.2 Effectiveness in context

The gap between perfect-use and typical-use failure rates is large — typically a factor of 5–10. This gap reflects the reality that fertility awareness methods require daily attention, consistent practice, mutual cooperation between partners, and willingness to abstain during the fertile window. Under crisis conditions (stress, disrupted routines, inadequate sleep, partner dynamics under pressure), typical-use failure rates may be at the higher end of the range or worse.

Honest assessment: Fertility awareness methods are substantially less effective than IUDs (<1% failure rate) or implants (<1% failure rate).22 For any individual woman, a FABM is a worse contraceptive than a copper IUD. At population scale, the difference is consequential: if 100,000 women rely on FABMs with a 15% typical-use failure rate, approximately 15,000 unintended pregnancies per year result. If the same 100,000 women have copper IUDs, approximately 600–800 unintended pregnancies result. The arithmetic is clear: copper IUD fabrication should be the primary long-term strategy. Fertility awareness methods are the bridge — necessary, valuable, but not sufficient alone.

3.3 Education programme

Fertility awareness education should be delivered through existing primary health networks — Family Planning NZ clinics, community midwives, GPs, Plunket nurses, and marae-based health services. The programme requires:

  • Educator training: A 2–4 week training module for health professionals, covering the physiology of fertility, method instruction, counselling skills, and common errors. Target: 200–500 trained educators within 6 months.
  • Printed materials: Charts, instructions, and quick-reference cards for each method. These can be printed domestically (Doc #5, Doc #29).
  • Thermometers: Basal body temperature measurement requires an accurate thermometer (to 0.1°C). NZ’s existing stock of clinical and household thermometers is large. Mercury thermometers, while disfavoured in peacetime, are durable and do not require batteries.
  • Community classes: Group education sessions are more efficient than individual instruction and provide peer support, which improves method adherence.

4. COPPER IUD LOCAL FABRICATION

4.1 What a copper IUD is

A copper IUD is a small (approximately 30–36 mm) T-shaped device inserted into the uterus for long-term contraception. The TCu380A — the most widely studied and most effective copper IUD — consists of:23

  • A polyethylene T-shaped frame
  • Copper wire wound around the vertical stem (approximately 176 mg of copper wire)
  • Copper sleeves on the horizontal arms (approximately 2 x 68.7 mg)
  • Total copper surface area: approximately 380 mm²
  • A monofilament retrieval thread attached to the base

The copper releases copper ions into the uterine cavity, creating an environment hostile to sperm and preventing fertilisation. It is non-hormonal, effective for up to 10 years, and has a failure rate of less than 1% per year.24

4.2 What NZ has

Copper wire: NZ has abundant copper wire from electrical infrastructure. Electrical-grade copper is 99.9%+ pure — more than adequate for IUD fabrication.25 The dependency chain for obtaining usable wire: identify and recover copper wire from decommissioned or salvageable electrical cabling; strip insulation (manual labour or controlled burning); clean and inspect for corrosion or contamination; draw or select wire of appropriate gauge (approximately 0.3–0.4 mm diameter for IUD winding — finer than most building wire, so existing fine-gauge wire stocks such as transformer winding wire or electronics wire should be prioritised; alternatively, wire can be drawn to finer gauge using a simple drawplate, which requires hardened steel tooling). The total copper requirement for 20,000 IUDs per year is approximately 6–7 kg — a negligible quantity relative to NZ’s copper stocks in electrical infrastructure, but sourcing the correct gauge is the practical constraint, not the total mass.

Frame material: The T-frame is polyethylene. NZ has polyethylene stock in various forms (packaging, pipe, container stock) but cannot produce new polyethylene without petrochemical feedstock (ethylene from oil or gas cracking — not available domestically). Dependency chain for polyethylene frames: salvage suitable polyethylene stock (high-density polyethylene preferred for rigidity); cut or injection-mould into T-frame shape using a precision jig or heated mould; dimensional tolerance is critical — frames outside the 30–36 mm range cause insertion difficulty or poor retention. If injection moulding: requires a small heated press and a machined metal mould (one-time fabrication by a toolmaker). If cutting from rod stock: requires a lathe or precision hand tools. Alternatives if polyethylene stock is exhausted: (a) stainless steel wire frames (used in some historical IUD designs such as the Lippes Loop predecessor — NZ Steel produces steel at Glenbrook, Doc #89, but medical-grade stainless requires specific alloy composition and corrosion resistance verification); (b) other biocompatible materials available in NZ, though biocompatibility testing is a prerequisite for any novel frame material.

Retrieval thread: Monofilament nylon or polyethylene thread. Available from existing fishing line, suture material, or textile stocks. Trivial quantities required.

Sterilisation: Autoclaving (steam sterilisation at 121°C for 15–30 minutes) is the standard method. NZ has autoclaves in every hospital, dental practice, and many veterinary practices. Ethylene oxide sterilisation is also available at some NZ facilities. Either method is adequate for IUD sterilisation.

4.3 Fabrication process

The fabrication process is mechanically simple compared with hormonal pharmaceutical production, but requires dimensional precision, sterile technique, and quality control infrastructure:

  1. Frame production: Cut or mould T-shaped frames from polyethylene stock (or bend from stainless steel wire). Each frame must be dimensionally consistent — variations in size affect insertion difficulty and device performance. A simple jig or mould ensures consistency.
  2. Copper winding: Wind copper wire tightly around the vertical stem of the frame. The wire gauge and winding density determine the copper surface area, which determines efficacy. Target: approximately 380 mm² total copper surface area, matching the TCu380A specification.
  3. Thread attachment: Attach monofilament retrieval thread to the base of the frame.
  4. Quality inspection: Visual and dimensional inspection of each device. Reject any device with loose copper winding, frame defects, or dimensional non-conformity.
  5. Sterilisation: Autoclave each device in sealed packaging.
  6. Packaging: Seal in sterile packaging for distribution.

Feasibility rating: [B]. The materials exist. The process is not chemically complex. The barriers are quality control (dimensional consistency, sterile manufacturing environment) and training (insertion practitioners). This is achievable within 1–2 years with dedicated effort. It is not a laboratory curiosity — copper IUDs have been fabricated in resource-limited settings internationally.26

Performance gap vs. commercial devices: Locally fabricated copper IUDs will likely be less consistent than factory-produced devices, particularly in the early production period. Expected differences: slightly higher expulsion rates (if frame dimensions vary), potentially higher insertion difficulty (if surface finish is rougher), and uncertain copper surface area consistency (affecting efficacy if below the 380 mm² target). Commercial TCu380A devices undergo ISO 7439 testing for biocompatibility, dimensional consistency, and copper dissolution rate — local production cannot replicate this full testing regime initially. The mitigation is rigorous post-insertion surveillance (Section 4.4) and iterative process improvement. Even with somewhat higher failure rates than commercial devices (perhaps 1–2% per year vs. 0.6–0.8% for commercial TCu380A), locally fabricated copper IUDs remain far more effective than fertility awareness methods (12–24% typical-use failure rate).

4.4 Quality assurance

The critical quality concern is not toxicity (copper is biocompatible at these quantities and has been used in IUDs since the 1960s) but device consistency and sterility.27 A poorly wound device may have inadequate copper surface area (reducing efficacy) or rough edges (increasing insertion difficulty or uterine injury risk). A non-sterile device causes endometritis.

Quality assurance protocol:

  • Fabrication in a dedicated clean environment (not necessarily a cleanroom — a well-maintained, dust-free workshop with hand hygiene and surface cleaning protocols is adequate for device assembly prior to autoclaving)
  • Dimensional inspection of every device against a specification template
  • Autoclave validation: regular biological indicator testing to confirm sterilisation cycle efficacy (standard hospital CSSD practice)
  • Batch tracking: every device traceable to its fabrication date, operator, and sterilisation cycle
  • Post-insertion surveillance: track outcomes (insertion success, expulsion, infection, pregnancy) for locally fabricated devices and compare with historical rates for commercial devices. Adjust fabrication process based on data.

4.5 Demand estimate

If copper IUDs become the primary long-acting contraceptive method in NZ:

  • Target population: approximately 200,000–300,000 women of reproductive age who want long-acting contraception
  • Device duration: 10 years (TCu380A)
  • Steady-state replacement rate: approximately 20,000–30,000 devices per year
  • Initial ramp-up: higher demand as women transition from depleting hormonal methods to IUDs — perhaps 30,000–50,000 insertions in the first 2–3 years of the programme

This is a substantial clinical workload. At approximately 15–30 minutes per insertion (including patient counselling, the procedure itself, and post-insertion observation),28 25,000 insertions per year requires approximately 6,000–12,500 clinician-hours — roughly 3–6 FTE practitioners dedicated to IUD insertion alone. With the distributed workforce of GPs, midwives, and Family Planning clinicians, this is achievable but requires active training expansion.

5. OTHER LOCAL PRODUCTION OPTIONS

5.1 Lambskin condoms

Before latex vulcanisation in the mid-19th century, condoms were made from animal membrane — typically lamb or sheep caecum (the blind pouch of the large intestine).29 NZ’s sheep flock (approximately 26 million animals) provides abundant raw material.30

Production process: The caecum is cleaned, scraped, soaked in alkaline solution, and dried or preserved. Each caecum produces approximately one condom. The resulting membrane condom is effective for pregnancy prevention but does not prevent STI transmission (the membrane pores are large enough for viral particles to pass through, unlike latex).31

Performance gap vs. latex condoms: Lambskin condoms have comparable pregnancy prevention rates to latex condoms (typical-use failure rate approximately 18% per year for both),32 but critically do not prevent viral STI transmission — membrane pores of approximately 1.5 μm pass viruses such as HIV, hepatitis B, and HPV while blocking sperm.33 They are also more expensive and time-consuming to produce per unit than latex condoms, and have a shorter shelf life unless preserved in appropriate solution. Sensation and durability differ from latex — lambskin membranes are thinner and less elastic, making them more prone to tearing if improperly sized or stored.

Feasibility: [B]. The process is historical and well-documented. NZ has the raw material. The barrier is establishing consistent production with adequate quality control (membrane integrity, sizing, preservation). This is achievable but should be lower priority than copper IUD fabrication — membrane condoms are less effective than IUDs for pregnancy prevention and do not address STI prevention.

5.2 Cervical caps and diaphragms

Cervical caps and diaphragms are reusable barrier devices inserted before intercourse. Historically made from rubber, they can potentially be fabricated from NZ’s existing silicone or rubber stocks. Typical-use failure rate: approximately 12–17% per year for diaphragms with spermicide; higher without.34

Performance gap vs. modern manufactured devices: Locally moulded diaphragms would likely have less consistent sizing and surface finish than factory-produced devices, potentially increasing failure rates above the already-moderate typical-use figures. Without nonoxynol-9 or equivalent spermicide (which NZ cannot produce locally), diaphragm efficacy drops further — typical-use failure rates without spermicide are estimated at 17–20% or higher.35

Feasibility: [C]. Requires precision moulding of silicone or rubber into specific sizes — the dependency chain includes: sourcing appropriate-grade silicone or rubber stock, fabricating moulds in multiple standard sizes (requires a skilled toolmaker), controlled-temperature curing, and quality inspection for defects. Raw material (silicone, vulcanised rubber) is available from existing stocks but finite and not renewable without petrochemical feedstock. Production is technically feasible but the clinical support infrastructure (fitting, sizing, patient education) limits scalability. Lower priority.

5.3 Withdrawal and lactational amenorrhoea

Two non-manufactured methods deserve mention:

Withdrawal (coitus interruptus): Typical-use failure rate approximately 20–22% per year; perfect-use approximately 4%.36 Requires no materials or training, but is substantially less effective than other methods. Not recommended as a primary method but will be used regardless of recommendations.

Lactational amenorrhoea method (LAM): Exclusive breastfeeding suppresses ovulation for approximately 6 months postpartum in most women. Typical-use failure rate approximately 2% in the first 6 months if three criteria are met: exclusive breastfeeding, amenorrhoea (no return of menses), and infant less than 6 months old.37 This is a useful method for the postpartum period and requires only breastfeeding support — which NZ’s midwifery and Plunket infrastructure is well-positioned to provide.

6. DISTRIBUTION AND ACCESS

Feasibility: [A] — NZ’s existing primary health network provides the delivery infrastructure. The constraint is supply, not distribution capacity.

6.1 Existing networks

NZ has a functional primary health network for contraceptive delivery:

  • Family Planning NZ: Approximately 30 clinics nationwide, specialising in sexual and reproductive health. The core specialist workforce for LARC insertion and contraceptive education.38
  • General practice: Approximately 3,500–4,000 GPs,39 many of whom prescribe oral contraceptives and some of whom perform LARC insertions.
  • Community midwives: Approximately 2,800–3,200 active midwives,40 many trained or trainable in IUD insertion.
  • Hospital outpatient clinics: Gynaecology departments at major hospitals provide LARC services.
  • Marae-based health services and Maori health providers: Important access points for Maori communities, which have higher unmet need for contraception and higher rates of unintended pregnancy.41

6.2 Access equity

Contraceptive access in NZ is already unevenly distributed. Under rationing, existing disparities risk widening:

  • Rural communities: Fewer LARC insertion practitioners. Some rural women must travel hours for IUD insertion. Training rural practitioners is the mitigation.
  • Maori and Pacific communities: Higher unintended pregnancy rates under current conditions. These communities should be prioritised for LARC access and fertility awareness education — not because of population control motives, but because unmet contraceptive demand is already highest in these populations.42
  • Young people: Adolescents face additional access barriers (transport, confidentiality, cost). Under rationing, adolescent access to contraception should be maintained through school-based health services and youth-friendly clinic settings.
  • Cost: Under the emergency pharmaceutical framework (Doc #4), contraceptive supplies should be distributed free of charge. Cost barriers to contraception are counterproductive when the downstream costs of unintended pregnancy are borne collectively.

7. DEMOGRAPHIC PROJECTIONS

7.1 Scenarios

The following projections estimate NZ’s annual birth count under different contraceptive availability assumptions, starting from a baseline of approximately 60,000 births per year:43

Scenario Contraceptive availability Estimated birth rate by Year 5 Estimated birth rate by Year 10
A: Full programme Copper IUD fabrication operational by Year 2; FAM education scaled; imported stocks rationed effectively 60,000–65,000 60,000–70,000
B: Partial programme Some local IUD production; limited FAM education; imported stocks depleted by Year 4 65,000–75,000 70,000–85,000
C: No programme No local production; no organised FAM education; imported stocks deplete naturally 70,000–80,000 80,000–100,000

Assumptions: These projections assume (a) NZ’s population of women of reproductive age remains approximately stable at 1.0–1.1 million; (b) desire for children does not change dramatically in either direction; (c) no significant change in partnership patterns. All three assumptions are uncertain. Psychological trauma and economic hardship may reduce fertility intentions in the short term; conversely, cultural shifts toward larger families in an agrarian recovery economy may increase them in the medium term. The projections are order-of-magnitude estimates, not precise forecasts.

7.2 Downstream implications

The difference between Scenario A and Scenario C is approximately 20,000–30,000 additional births per year by Year 10. Over a decade, this cumulates to roughly 100,000–200,000 additional people. The implications for recovery planning:

  • Food: At 2,000–2,500 kcal/day per person (varying by age and activity level; see Doc #3), 150,000 additional people require approximately 110–135 billion additional kilocalories per year — equivalent to the caloric output of roughly 30,000–50,000 hectares of cropping land under nuclear winter yield assumptions (Doc #75). This is within NZ’s agricultural capacity but represents a significant additional land allocation demand.
  • Housing: 150,000 additional people require roughly 40,000–60,000 additional dwellings over time, depending on household size assumptions under recovery conditions (Doc #162).
  • Education: 150,000 additional children require proportionate expansion of teaching workforce and school infrastructure (Doc #157).
  • Workforce: These children enter the workforce 15–20 years later. In the interim, they are dependents. The recovery workforce is smaller, not larger, during the dependency phase.

These are not arguments against having children. They are arguments for ensuring that the children born are wanted and planned, so that the recovery programme can allocate resources effectively.

8. ETHICAL FRAMING

8.1 Reproductive autonomy under scarcity

This document recommends making contraception available, not mandating its use. The distinction is non-negotiable. Compulsory contraception, sterilisation programmes, or birth quotas are:

  • Ethically indefensible — reproductive autonomy is a fundamental dimension of human dignity
  • Practically counterproductive — coercive measures provoke resistance, non-compliance, and social instability that undermine recovery far more than the demographic pressures they aim to address
  • Historically discredited — every historical programme of coercive population control has produced atrocities, backlash, and long-term social damage44

The recovery programme’s interest is in ensuring that people who want to prevent pregnancy can do so effectively. The programme has no interest in preventing pregnancies that people want.

8.2 The tension between individual choice and collective constraint

Under food rationing, each additional person reduces per-capita food availability for everyone. This creates a tension: individual reproductive decisions have collective consequences. This tension is real and should be acknowledged, not ignored.

The resolution is not coercion but information and access. If people understand the food supply situation (Doc #2, Doc #3), have access to effective contraception, and can make informed decisions, most will calibrate their family planning accordingly — as people do in every society where contraception is available and food security is uncertain. The government’s role is to provide the information and the means, not to override the decision.

If the food situation becomes genuinely critical (Doc #3 projections show caloric deficit), the appropriate response is intensified voluntary contraceptive provision and honest public communication about the food-population relationship — not reproductive coercion. The line between encouragement and coercion must be maintained vigilantly, particularly under stress when governments are tempted to mandate what they cannot persuade.

8.3 Cultural and religious diversity

NZ’s population includes communities with diverse views on contraception — Catholic, conservative Protestant, some Maori and Pacific communities, and others may have objections to specific methods or to contraception generally. The programme should:

  • Provide information about all available methods, including natural methods (fertility awareness) that may be more acceptable to communities with religious objections to artificial contraception
  • Respect individual and family decisions not to use contraception
  • Not present fertility awareness methods as inferior because they align with religious values — they are less effective than IUDs, which should be stated honestly, but they are legitimate choices
  • Ensure that community health providers from diverse backgrounds are included in the education programme

CRITICAL UNCERTAINTIES

Uncertainty Impact if wrong Resolution method
Actual contraceptive stock levels Over-estimated stock means earlier depletion and larger gap period; under-estimated means unnecessary urgency National inventory (Recommended Action #1)
Copper IUD fabrication quality If locally made IUDs are less effective or cause more complications than commercial devices, the programme loses credibility Rigorous quality assurance, post-insertion surveillance, iterative improvement
LARC insertion workforce capacity If too few practitioners are trained, IUD access becomes a bottleneck regardless of device availability Aggressive training expansion (Recommended Action #8)
Fertility awareness method uptake and adherence If FAM typical-use failure rates are at the high end (20%+), the demographic impact is substantial Intensive education, ongoing support, realistic expectations about efficacy
Population fertility intentions post-event If cultural shifts increase desire for larger families, contraceptive demand may actually decrease — making demographic projections worse than Scenario C Monitor actual birth data; adjust planning assumptions annually
Hormonal contraceptive shelf-life extension If OCP potency degrades faster than SLEP estimates for other drug classes, the pill supply shortens NZ-specific stability testing (Doc #116); conservative prescribing assumptions
Public acceptance of locally fabricated IUDs If women do not trust locally made devices, uptake will be low regardless of device quality Transparent quality data, clinical endorsement, early adopter experience sharing
STI rates without condoms If condom stocks deplete and no barrier alternative is available, STI rates (including HIV, chlamydia, gonorrhoea) will increase Lambskin condom production (pregnancy prevention only); STI treatment protocols; behavioural public health messaging

CROSS-REFERENCES

Document Relevance
Doc #3 — Food Rationing Population growth increases food demand under rationing. Demographic projections feed into food planning models.
Doc #4 — Pharmaceutical and Medical Supply Management Contraceptive stocks managed through the national pharmaceutical management framework.
Doc #89 — NZ Steel Glenbrook Steel production relevant to stainless steel IUD frame fabrication option.
Doc #116 — Pharmaceutical Rationing and Shelf-Life Extension Oral contraceptive pills classified as Triage Category 3 (Important). Shelf-life extension applicable to hormonal contraceptives.
Doc #119 — Local Pharmaceutical Production Hormonal contraceptive synthesis is not a near-term local production target; copper IUD fabrication is the viable path.
Doc #123 — Midwifery and Maternity Care Maternity care demand directly affected by birth rate. Midwifery workforce is also the primary LARC insertion workforce.
Doc #125 — Public Health STI prevention strategy affected by condom supply depletion.
Doc #145 — Workforce Reallocation Dependency ratio implications of population growth under different contraceptive scenarios.
Doc #158 — School Curriculum Education demand scales with birth rate.
Doc #163 — Housing and Insulation Housing demand scales with population growth.

  1. NZ has no domestic pharmaceutical manufacturing of contraceptive products. All oral contraceptive pills, injectable contraceptives, implants, IUDs, and condoms are imported through international supply chains. PHARMAC contracts with overseas manufacturers for funded products; commercial products (condoms) are imported by private distributors. Stock level estimates (3–6 months for high-turnover items, 6–12 months for low-turnover items) are based on standard NZ pharmaceutical wholesale pipeline norms — actual figures would need verification through the Doc #4 national inventory process.↩︎

  2. Stats NZ, “Births and deaths: Year ended December 2023 (provisional).” https://www.stats.govt.nz/ — NZ recorded approximately 57,000–62,000 live births per year in recent years. The figure fluctuates; 60,000 is used as a round working estimate.↩︎

  3. Estimate based on the assumption that contraceptive availability declines progressively over 3–7 years and that unmet need converts to unintended pregnancies at rates consistent with international experience in settings where contraception becomes unavailable. The 70,000–80,000 figure is an order-of-magnitude projection, not a precise forecast. Historical experience in countries where contraceptive access has been disrupted (e.g., Romania after 1966 abortion ban, various conflict zones) suggests birth rate increases of 20–50% are plausible.↩︎

  4. PHARMAC pharmaceutical schedule and dispensing data. https://www.pharmac.govt.nz/ — PHARMAC funds combined oral contraceptives, progestogen-only pills, medroxyprogesterone acetate injection (Depo-Provera), levonorgestrel subdermal implant (Jadelle), copper IUDs, and levonorgestrel-releasing IUDs (Mirena, Kyleena). Dispensing volumes are commercially sensitive; the estimates in this document are based on available aggregate data and should be verified through the Doc #4 inventory process.↩︎

  5. Estimate. The number of practitioners trained and competent in IUD and implant insertion in NZ is not publicly reported as an aggregate figure. Family Planning NZ clinicians, a subset of GPs with specific LARC training, hospital gynaecologists, and some midwives have these skills. Family Planning NZ trains approximately 200–300 practitioners per year in LARC insertion courses. The total active insertion-competent workforce is estimated at 1,500–2,000 based on training throughput and workforce size.↩︎

  6. NZ Health Survey data and Family Planning NZ reports. https://www.familyplanning.org.nz/ — Contraceptive prevalence and method mix data for NZ are reported in the NZ Health Survey and by Family Planning NZ. Approximately 70–75% of women of reproductive age use some form of contraception; approximately 50–60% use modern methods (hormonal, LARC, or barrier). Specific method share estimates are approximate.↩︎

  7. PHARMAC pharmaceutical schedule and dispensing data. https://www.pharmac.govt.nz/ — PHARMAC funds combined oral contraceptives, progestogen-only pills, medroxyprogesterone acetate injection (Depo-Provera), levonorgestrel subdermal implant (Jadelle), copper IUDs, and levonorgestrel-releasing IUDs (Mirena, Kyleena). Dispensing volumes are commercially sensitive; the estimates in this document are based on available aggregate data and should be verified through the Doc #4 inventory process.↩︎

  8. NZ Health Survey data and Family Planning NZ reports. https://www.familyplanning.org.nz/ — Contraceptive prevalence and method mix data for NZ are reported in the NZ Health Survey and by Family Planning NZ. Approximately 70–75% of women of reproductive age use some form of contraception; approximately 50–60% use modern methods (hormonal, LARC, or barrier). Specific method share estimates are approximate.↩︎

  9. PHARMAC pharmaceutical schedule and dispensing data. https://www.pharmac.govt.nz/ — PHARMAC funds combined oral contraceptives, progestogen-only pills, medroxyprogesterone acetate injection (Depo-Provera), levonorgestrel subdermal implant (Jadelle), copper IUDs, and levonorgestrel-releasing IUDs (Mirena, Kyleena). Dispensing volumes are commercially sensitive; the estimates in this document are based on available aggregate data and should be verified through the Doc #4 inventory process.↩︎

  10. NZ Health Survey data and Family Planning NZ reports. https://www.familyplanning.org.nz/ — Contraceptive prevalence and method mix data for NZ are reported in the NZ Health Survey and by Family Planning NZ. Approximately 70–75% of women of reproductive age use some form of contraception; approximately 50–60% use modern methods (hormonal, LARC, or barrier). Specific method share estimates are approximate.↩︎

  11. Family Planning NZ. https://www.familyplanning.org.nz/ — A national not-for-profit organisation operating approximately 30 clinics across NZ, providing contraceptive services, STI testing, and reproductive health education. Family Planning NZ clinicians are the largest concentrated group of LARC insertion specialists in NZ.↩︎

  12. NZ has no domestic pharmaceutical manufacturing of contraceptive products. All oral contraceptive pills, injectable contraceptives, implants, IUDs, and condoms are imported through international supply chains. PHARMAC contracts with overseas manufacturers for funded products; commercial products (condoms) are imported by private distributors. Stock level estimates (3–6 months for high-turnover items, 6–12 months for low-turnover items) are based on standard NZ pharmaceutical wholesale pipeline norms — actual figures would need verification through the Doc #4 national inventory process.↩︎

  13. SLEP data (Doc #116, Appendix A) demonstrates that many solid oral dose forms retain potency 5–15 years beyond labeled expiry. However, oral contraceptive pills contain low-dose hormones (ethinyl estradiol at 20–35 mcg; various progestogens) where even modest potency decline may affect efficacy. No SLEP data specific to oral contraceptive formulations has been published. The conservative extension estimate of 2–3 years beyond labeled expiry reflects this uncertainty. NZ-specific stability testing (Doc #116) should include oral contraceptive formulations as a priority.↩︎

  14. WHO. “Mechanism of action, safety and efficacy of intrauterine devices.” Technical Report Series No. 753, 1987. Also: ACOG Practice Bulletin No. 186: Long-Acting Reversible Contraception: Implants and Intrauterine Devices. 2017. The TCu380A copper IUD has been in use since the 1980s, with extensive safety and efficacy data. Failure rate: 0.6–0.8% per year. Approved duration: 10 years. The copper acts primarily by preventing fertilisation through toxic effects on sperm.↩︎

  15. WHO. “Mechanism of action, safety and efficacy of intrauterine devices.” Technical Report Series No. 753, 1987. Also: ACOG Practice Bulletin No. 186: Long-Acting Reversible Contraception: Implants and Intrauterine Devices. 2017. The TCu380A copper IUD has been in use since the 1980s, with extensive safety and efficacy data. Failure rate: 0.6–0.8% per year. Approved duration: 10 years. The copper acts primarily by preventing fertilisation through toxic effects on sperm.↩︎

  16. NZ does not have a natural rubber (Hevea brasiliensis) industry — the tree requires tropical climate. All latex products in NZ are imported. Synthetic rubber (polyisoprene) condoms are also imported. Once stocks are exhausted, NZ has no pathway to produce latex or synthetic rubber condoms locally.↩︎

  17. Frank-Herrmann P, et al. “The effectiveness of a fertility awareness based method to avoid pregnancy in relation to a couple’s sexual behaviour during the fertile time: a prospective longitudinal study.” Human Reproduction 22(5):1310–1319, 2007. Also: Trussell J. “Contraceptive failure in the United States.” Contraception 83(5):397–404, 2011. Fertility awareness method efficacy varies substantially by specific method, teaching quality, and user adherence. The sympto-thermal method has the strongest efficacy data among FABMs.↩︎

  18. Frank-Herrmann P, et al. “The effectiveness of a fertility awareness based method to avoid pregnancy in relation to a couple’s sexual behaviour during the fertile time: a prospective longitudinal study.” Human Reproduction 22(5):1310–1319, 2007. Also: Trussell J. “Contraceptive failure in the United States.” Contraception 83(5):397–404, 2011. Fertility awareness method efficacy varies substantially by specific method, teaching quality, and user adherence. The sympto-thermal method has the strongest efficacy data among FABMs.↩︎

  19. Trussell J. “Contraceptive failure in the United States.” Contraception 83(5):397–404, 2011. The standard reference for contraceptive efficacy data. First-year failure rates (typical use): copper IUD 0.8%; implant 0.05%; combined pill 9%; male condom 18%; fertility awareness methods 12–24%; withdrawal 22%. Perfect-use failure rates are substantially lower for all methods.↩︎

  20. Frank-Herrmann P, et al. “The effectiveness of a fertility awareness based method to avoid pregnancy in relation to a couple’s sexual behaviour during the fertile time: a prospective longitudinal study.” Human Reproduction 22(5):1310–1319, 2007. Also: Trussell J. “Contraceptive failure in the United States.” Contraception 83(5):397–404, 2011. Fertility awareness method efficacy varies substantially by specific method, teaching quality, and user adherence. The sympto-thermal method has the strongest efficacy data among FABMs.↩︎

  21. Frank-Herrmann P, et al. “The effectiveness of a fertility awareness based method to avoid pregnancy in relation to a couple’s sexual behaviour during the fertile time: a prospective longitudinal study.” Human Reproduction 22(5):1310–1319, 2007. Also: Trussell J. “Contraceptive failure in the United States.” Contraception 83(5):397–404, 2011. Fertility awareness method efficacy varies substantially by specific method, teaching quality, and user adherence. The sympto-thermal method has the strongest efficacy data among FABMs.↩︎

  22. Trussell J. “Contraceptive failure in the United States.” Contraception 83(5):397–404, 2011. The standard reference for contraceptive efficacy data. First-year failure rates (typical use): copper IUD 0.8%; implant 0.05%; combined pill 9%; male condom 18%; fertility awareness methods 12–24%; withdrawal 22%. Perfect-use failure rates are substantially lower for all methods.↩︎

  23. WHO. “Mechanism of action, safety and efficacy of intrauterine devices.” Technical Report Series No. 753, 1987. Also: ACOG Practice Bulletin No. 186: Long-Acting Reversible Contraception: Implants and Intrauterine Devices. 2017. The TCu380A copper IUD has been in use since the 1980s, with extensive safety and efficacy data. Failure rate: 0.6–0.8% per year. Approved duration: 10 years. The copper acts primarily by preventing fertilisation through toxic effects on sperm.↩︎

  24. WHO. “Mechanism of action, safety and efficacy of intrauterine devices.” Technical Report Series No. 753, 1987. Also: ACOG Practice Bulletin No. 186: Long-Acting Reversible Contraception: Implants and Intrauterine Devices. 2017. The TCu380A copper IUD has been in use since the 1980s, with extensive safety and efficacy data. Failure rate: 0.6–0.8% per year. Approved duration: 10 years. The copper acts primarily by preventing fertilisation through toxic effects on sperm.↩︎

  25. NZ’s in-service copper stock in electrical infrastructure — wiring in buildings, power distribution, transformers, telecommunications cable — is difficult to quantify precisely but is estimated at tens of thousands of tonnes or more, based on NZ’s approximately 2 million buildings plus national grid and telecommunications infrastructure. The copper requirement for 25,000 IUDs per year at approximately 300 mg per device is approximately 7.5 kg — a negligible quantity relative to any plausible estimate of total copper stocks. Copper purity for electrical wire (99.9%+) exceeds what is needed for IUD fabrication. The practical constraint is sourcing wire of appropriate gauge (see Section 4.2), not total copper availability.↩︎

  26. Fabrication of copper IUDs in resource-limited settings has been documented in several countries. The Population Council, which developed the TCu380A, has published specifications and fabrication guidance. Also: Sivin I, Batár I. “State-of-the-art of non-hormonal methods of contraception: IV. Natural family planning, male and female sterilisation.” European Journal of Contraception and Reproductive Health Care 15(4):255–263, 2010. The key insight is that a copper IUD is a mechanically simple device — the complexity is in quality assurance and clinical insertion, not in the device itself.↩︎

  27. WHO. “Mechanism of action, safety and efficacy of intrauterine devices.” Technical Report Series No. 753, 1987. Also: ACOG Practice Bulletin No. 186: Long-Acting Reversible Contraception: Implants and Intrauterine Devices. 2017. The TCu380A copper IUD has been in use since the 1980s, with extensive safety and efficacy data. Failure rate: 0.6–0.8% per year. Approved duration: 10 years. The copper acts primarily by preventing fertilisation through toxic effects on sperm.↩︎

  28. IUD insertion procedure time varies by practitioner experience, patient factors (nulliparous vs. multiparous), and whether the visit includes counselling. The procedure itself typically takes 5–10 minutes; with pre-insertion counselling, consent, and post-insertion observation, total appointment time is 15–30 minutes. Based on Family Planning NZ clinical guidelines and RANZCOG practice standards.↩︎

  29. Collier A. The Humble Little Condom: A History. Prometheus Books, 2007. Animal membrane condoms (primarily from lamb caecum) were the standard from at least the 18th century through the vulcanisation of rubber in the 1840s. They remain commercially available today (marketed as “natural” or “lambskin” condoms) for users with latex allergies. They are effective for pregnancy prevention but do not prevent viral STI transmission due to natural pores in the membrane (approximately 1.5 μm — smaller than sperm but larger than viruses).↩︎

  30. Stats NZ agricultural statistics. NZ’s sheep population is approximately 26 million. At standard processing rates, the lamb slaughter provides ample caecum material for condom production. The limiting factor is not raw material availability but establishing a consistent cleaning, preparation, and quality control process.↩︎

  31. Collier A. The Humble Little Condom: A History. Prometheus Books, 2007. Animal membrane condoms (primarily from lamb caecum) were the standard from at least the 18th century through the vulcanisation of rubber in the 1840s. They remain commercially available today (marketed as “natural” or “lambskin” condoms) for users with latex allergies. They are effective for pregnancy prevention but do not prevent viral STI transmission due to natural pores in the membrane (approximately 1.5 μm — smaller than sperm but larger than viruses).↩︎

  32. Trussell J. “Contraceptive failure in the United States.” Contraception 83(5):397–404, 2011. The standard reference for contraceptive efficacy data. First-year failure rates (typical use): copper IUD 0.8%; implant 0.05%; combined pill 9%; male condom 18%; fertility awareness methods 12–24%; withdrawal 22%. Perfect-use failure rates are substantially lower for all methods.↩︎

  33. Collier A. The Humble Little Condom: A History. Prometheus Books, 2007. Animal membrane condoms (primarily from lamb caecum) were the standard from at least the 18th century through the vulcanisation of rubber in the 1840s. They remain commercially available today (marketed as “natural” or “lambskin” condoms) for users with latex allergies. They are effective for pregnancy prevention but do not prevent viral STI transmission due to natural pores in the membrane (approximately 1.5 μm — smaller than sperm but larger than viruses).↩︎

  34. Trussell J. “Contraceptive failure in the United States.” Contraception 83(5):397–404, 2011. The standard reference for contraceptive efficacy data. First-year failure rates (typical use): copper IUD 0.8%; implant 0.05%; combined pill 9%; male condom 18%; fertility awareness methods 12–24%; withdrawal 22%. Perfect-use failure rates are substantially lower for all methods.↩︎

  35. Trussell J. “Contraceptive failure in the United States.” Contraception 83(5):397–404, 2011. The standard reference for contraceptive efficacy data. First-year failure rates (typical use): copper IUD 0.8%; implant 0.05%; combined pill 9%; male condom 18%; fertility awareness methods 12–24%; withdrawal 22%. Perfect-use failure rates are substantially lower for all methods.↩︎

  36. Trussell J. “Contraceptive failure in the United States.” Contraception 83(5):397–404, 2011. The standard reference for contraceptive efficacy data. First-year failure rates (typical use): copper IUD 0.8%; implant 0.05%; combined pill 9%; male condom 18%; fertility awareness methods 12–24%; withdrawal 22%. Perfect-use failure rates are substantially lower for all methods.↩︎

  37. WHO/UNICEF. “Lactational amenorrhoea method (LAM).” In: Family Planning: A Global Handbook for Providers. 2018 update. LAM is effective (98% in the first 6 months) only when all three criteria are met: exclusive or near-exclusive breastfeeding, amenorrhoea, and infant under 6 months. Once any criterion lapses, another method should be adopted.↩︎

  38. Family Planning NZ. https://www.familyplanning.org.nz/ — A national not-for-profit organisation operating approximately 30 clinics across NZ, providing contraceptive services, STI testing, and reproductive health education. Family Planning NZ clinicians are the largest concentrated group of LARC insertion specialists in NZ.↩︎

  39. Medical Council of New Zealand workforce data. https://www.mcnz.org.nz/ — The Medical Council’s annual workforce survey reports approximately 3,500–4,000 vocationally registered GPs in NZ. Not all GPs provide LARC services; the subset trained in IUD insertion is estimated in footnote [^4].↩︎

  40. Midwifery Council of New Zealand workforce data. https://www.midwiferycouncil.health.nz/ — The Midwifery Council reports approximately 3,000 midwives holding annual practising certificates, of whom approximately 2,800–3,200 are in active clinical practice. Midwifery workforce size and LARC training capacity are also discussed in Doc #123.↩︎

  41. Ministry of Health. “Tatau Kahukura: Maori Health Chart Book” and NZ Health Survey data. https://www.health.govt.nz/ — Maori women have higher rates of unintended pregnancy and lower rates of LARC use compared with NZ European women. Pacific women show similar patterns. These disparities reflect access barriers, cost barriers (reduced under PHARMAC funding but not eliminated), and cultural factors — not lack of interest in family planning.↩︎

  42. Ministry of Health. “Tatau Kahukura: Maori Health Chart Book” and NZ Health Survey data. https://www.health.govt.nz/ — Maori women have higher rates of unintended pregnancy and lower rates of LARC use compared with NZ European women. Pacific women show similar patterns. These disparities reflect access barriers, cost barriers (reduced under PHARMAC funding but not eliminated), and cultural factors — not lack of interest in family planning.↩︎

  43. Stats NZ, “Births and deaths: Year ended December 2023 (provisional).” https://www.stats.govt.nz/ — NZ recorded approximately 57,000–62,000 live births per year in recent years. The figure fluctuates; 60,000 is used as a round working estimate.↩︎

  44. The most notorious examples include Romania’s 1966 Decree 770 (banning abortion and restricting contraception, which doubled the birth rate but caused enormous maternal mortality from unsafe abortion and overwhelmed orphanages); China’s one-child policy (1980–2015, which involved widespread forced abortion and sterilisation); and India’s Emergency-era sterilisation programme (1975–1977). Each produced lasting social damage and is now widely regarded as a human rights violation.↩︎

← Back to Library Index